Understanding What Causes Lp(a) to Be Out of Range on Your Lab Report

What Is Lp(a) and Why Does It Appear on Your Lab Report?

Lipoprotein(a) — written as Lp(a) and pronounced "L-P-little-a" — is a low-density lipoprotein particle with an additional protein called apolipoprotein(a) attached to it. This structural quirk makes it far stickier than ordinary LDL, meaning it accumulates in arterial walls more aggressively, promotes inflammation, and interferes with the body's clot-dissolving mechanisms (Kamstrup et al., Journal of the American College of Cardiology 2010; PMID: 20447528).

The reason Lp(a) now appears more frequently on lab reports is straightforward: cardiovascular researchers, cardiologists, and preventive medicine physicians have pushed hard for routine screening after large-scale Mendelian randomization studies confirmed it is an independent causal risk factor for heart attack, stroke, and aortic valve stenosis — not merely a bystander marker (Burgess et al., Journal of Internal Medicine 2018; PMID: 29504226).

Reference Ranges and Optimal Levels

Lp(a) is typically measured in mg/dL or nmol/L, and the units matter because conversion between them is not a simple 1:1 ratio.

The European Atherosclerosis Society consensus panel recommends considering Lp(a) > 50 mg/dL (> 125 nmol/L) a major independent risk factor warranting aggressive management of all other cardiovascular risk factors (Nordestgaard et al., European Heart Journal 2010; PMID: 20965889).

---

What Causes Lp(a) to Be Out of Range?

This is the question most patients ask first — and the answer is both reassuring and sobering.

1. Genetics: The Dominant Driver

Approximately 70–90% of an individual's Lp(a) level is determined by variants in the LPA gene on chromosome 6. The gene controls the size and number of kringle IV type 2 (KIV-2) repeats in apolipoprotein(a); fewer repeats correlate with higher plasma Lp(a) concentrations. This is why Lp(a) is largely non-responsive to lifestyle changes like diet and exercise — it's largely encoded at birth.

Certain ethnic groups carry a disproportionate burden. People of African ancestry have Lp(a) levels roughly two to three times higher on average than people of European ancestry, and this difference is at least partially explained by variation in LPA allele frequency (Guan et al., JAMA Cardiology 2015; PMID: 27437591).

2. Hormonal and Endocrine Influences

While genetics is the primary driver, several hormonal states modulate Lp(a) meaningfully:

• Estrogen deficiency: Postmenopausal women frequently see Lp(a) rise as estrogen levels fall. Estrogen appears to suppress hepatic Lp(a) production, so declining levels remove that brake.
• Hypothyroidism: Low thyroid hormone activity reduces the clearance rate of Lp(a) and raises its plasma concentration — an important connection we'll explore in depth below.
• Insulin resistance: Some evidence suggests that hyperinsulinemia may modestly upregulate Lp(a) synthesis, though this relationship is weaker than the genetic and hormonal links.

3. Kidney Disease

Nephrotic syndrome and chronic kidney disease are associated with significantly elevated Lp(a). Reduced renal clearance of apo(a) fragments combined with increased hepatic synthesis drives levels upward. Patients with end-stage renal disease can have Lp(a) values several times their genetic baseline.

4. Acute Inflammation and Fibrinogen

Lp(a) behaves as a mild acute-phase reactant. During periods of significant systemic inflammation — infection, surgery, trauma — levels can temporarily spike. This overlap with other inflammatory biomarkers is one reason fibrinogen is sometimes measured alongside Lp(a) in cardiovascular risk panels.

5. Medications That Worsen Lp(a)

• Niacin (at pharmacological doses ≥ 1g/day) is one of the few agents that lowers Lp(a), so stopping niacin can raise it.
• Growth hormone therapy may elevate Lp(a) in some patients.
• Interestingly, statins — the most commonly prescribed lipid-lowering drugs — do not lower Lp(a) and some evidence suggests they may mildly raise it, which is a key reason Lp(a) screening is valuable even in statin-treated patients.

---

What Causes Fibrinogen to Be Out of Range?

Fibrinogen is a plasma protein that is the direct precursor to fibrin — the material that forms blood clots. It is also an acute-phase protein, meaning liver production surges during inflammation. Fibrinogen is relevant to the Lp(a) conversation for two reasons: both are cardiovascular risk biomarkers, and Lp(a) structurally mimics plasminogen, the enzyme that dissolves fibrin clots.

Elevated fibrinogen (> 400 mg/dL) can result from:

• Chronic low-grade inflammation (metabolic syndrome, obesity, smoking)
• Autoimmune conditions and active infections
• Pregnancy
• Cardiovascular disease itself

Low fibrinogen (< 200 mg/dL) is less common and may indicate:

• Disseminated intravascular coagulation (DIC)
• Severe liver failure (since the liver synthesizes fibrinogen)
• Rare inherited afibrinogenemia

The prognostic significance of fibrinogen is well established: a meta-analysis of over 150,000 patients demonstrated that fibrinogen levels in the top third of the population distribution roughly double the risk of coronary heart disease and stroke compared to those in the bottom third (Danesh et al., JAMA 2005; PMID: 15687315).

Because fibrinogen reflects overall inflammatory tone, strategies that reduce systemic inflammation — addressing metabolic health, optimizing micronutrient status, resolving sleep deficits — tend to modestly lower fibrinogen over time.

---

The Thyroid Connection: TSH, Free T3, and Free T4

One of the most clinically underappreciated drivers of elevated Lp(a) is thyroid dysfunction. The relationship is direct enough that many preventive cardiologists now request a full thyroid panel — including TSH, free T4, and free T3 — whenever they see an unexpectedly high Lp(a).

What Causes TSH to Be Out of Range?

Thyroid-stimulating hormone (TSH) is the pituitary's signal to the thyroid gland. When thyroid hormone production falls (hypothyroidism), the pituitary compensates by producing more TSH. The standard reference range for TSH is roughly 0.5–4.5 mIU/L, though many functional and integrative practitioners target 1.0–2.5 mIU/L for optimal metabolic health.

Causes of elevated TSH include:

• Hashimoto's thyroiditis (autoimmune thyroid destruction)
• Iodine deficiency
• Post-thyroidectomy
• Certain medications (lithium, amiodarone)
• Pituitary overproduction (rare TSH-secreting adenoma leads to high TSH and high thyroid hormones)

Causes of suppressed TSH include:

• Graves' disease (autoimmune hyperthyroidism)
• Excess thyroid hormone supplementation
• Toxic nodular goiter

Relevant to Lp(a): even subclinical hypothyroidism — defined as elevated TSH with normal free T4 — has been associated with measurably higher Lp(a) concentrations. Correcting thyroid function with appropriate therapy often produces a clinically meaningful reduction in Lp(a).

What Causes Free T4 to Be Out of Range?

Free T4 (thyroxine) is the primary secretory product of the thyroid gland and the precursor to the biologically active hormone free T3. Typical reference range for free T4: 0.8–1.8 ng/dL.

Low free T4 occurs in primary hypothyroidism (thyroid gland failure) or secondary hypothyroidism (pituitary or hypothalamic failure). Elevated free T4 points to hyperthyroidism — Graves' disease being the most common cause.

From a cardiovascular standpoint, low free T4 reduces the rate at which the liver clears Lp(a) particles, leading to accumulation in plasma. Normalizing T4 levels through thyroid hormone therapy has been shown in several clinical series to reduce Lp(a) by 20–30% in hypothyroid patients.

What Causes Free T3 to Be Out of Range?

Free T3 (triiodothyronine) is the most metabolically active thyroid hormone. It's produced both by direct thyroid secretion and by peripheral conversion of T4 via deiodinase enzymes. Reference range: approximately 2.3–4.2 pg/mL.

Low free T3 can occur even with a "normal" TSH, particularly in:

• Chronic illness or caloric restriction ("euthyroid sick syndrome" or "low T3 syndrome")
• Selenium deficiency, which impairs the deiodinase enzymes responsible for T4→T3 conversion
• Elevated reverse T3 (rT3) blocking receptor sites

Elevated free T3 is seen in hyperthyroidism, T3 thyrotoxicosis, or excess supplementation.

The free T3 connection to Lp(a) is less direct than the T4 pathway, but since T3 is the hormone that actually binds thyroid receptors in liver cells and governs cholesterol and lipoprotein metabolism, suboptimal T3 even with technically normal TSH and T4 may contribute to unfavorable lipid profiles including elevated Lp(a).

This is why a comprehensive thyroid panel — not just TSH — provides a clearer picture of the thyroid-cardiovascular interface.

---

Can You Lower Lp(a) Naturally?

This is the most common follow-up question patients ask after receiving an elevated result. The honest answer requires nuance:

What doesn't work well:

• Standard dietary changes (low-fat, Mediterranean, ketogenic) produce minimal Lp(a) reduction because Lp(a) is predominantly genetically regulated
• Aerobic exercise, while excellent for overall cardiovascular health, does not significantly lower Lp(a)
• Most conventional lipid-lowering medications (statins, ezetimibe, fibrates) have little to no effect on Lp(a)

What shows genuine promise:

1. Niacin (nicotinic acid): At doses of 1–3 g/day, niacin reduces Lp(a) by approximately 20–30%. Its use is limited by flushing, glucose effects, and the fact that clinical outcomes trials (AIM-HIGH, HPS2-THRIVE) did not demonstrate additional cardiovascular benefit over statins in already-treated patients.
2. PCSK9 inhibitors: Evolocumab and alirocumab lower Lp(a) by approximately 20–30% as a secondary effect — their primary action is LDL reduction.
3. RNA-targeted therapies: Pelacarsen (an antisense oligonucleotide targeting LPA mRNA) reduced Lp(a) by up to 80% in phase 2 trials and is currently in a large phase 3 cardiovascular outcomes trial (HORIZON). This represents the most promising near-future treatment for high-Lp(a) patients.
4. Addressing modifiable amplifiers: Optimizing thyroid function, reducing systemic inflammation, correcting nutritional deficiencies, and improving metabolic health won't eliminate genetically elevated Lp(a) but can remove the conditions that make it worse.

For people with borderline Lp(a) elevations (30–50 mg/dL) whose levels are being amplified by thyroid dysfunction, nutrient deficiencies, or chronic inflammation, addressing those root causes can shift the clinical picture meaningfully.

---

What This Means for Your Formula

If your Lp(a) is elevated, the most impactful action is working with your physician on medical management — particularly if levels exceed 50 mg/dL. But the nutritional and hormonal context surrounding Lp(a) creates real opportunities for precision supplementation.

Omega-3 fatty acids (EPA/DHA): High-dose omega-3s are well established for reducing triglycerides and systemic inflammation. While they do not reliably lower Lp(a) itself, they address the inflammatory environment that makes elevated Lp(a) more dangerous. Ones includes pharmaceutical-grade EPA/DHA dosed to clinical ranges, calibrated based on your triglyceride and inflammatory marker results from lab data.

Thyroid Support blend: Because hypothyroidism is a modifiable amplifier of Lp(a), Ones' proprietary Thyroid Support system blend includes nutrients critical to thyroid hormone synthesis and conversion — including the selenium cofactors that support the deiodinase enzymes responsible for T4-to-T3 conversion. If your lab results flag low free T3 or elevated TSH alongside high Lp(a), your Ones formula may incorporate this blend as part of an integrated response.

Vitamin D3 + K2 (MK-7): Vitamin D insufficiency correlates with impaired vascular endothelial function and elevated cardiovascular risk biomarkers. K2 as MK-7 supports appropriate calcium metabolism in arterial walls. When your blood work shows suboptimal 25-OH vitamin D alongside elevated Lp(a), this pairing addresses the vascular health dimension of the overall risk picture.

Ones' AI health practitioner analyzes your full lab panel — not just Lp(a) in isolation — and builds a formula that addresses the system-level findings simultaneously, whether that's a 6 or 9-capsule daily plan calibrated to your specific needs.

Explore how understanding your lipid panel markers connects to broader cardiovascular risk assessment, and learn more about thyroid lab results and what they mean for your metabolic health. If you're interested in how omega-3 dosing affects cardiovascular biomarkers, that context is also relevant to understanding the full picture around Lp(a).

---

Key Takeaways

• Lp(a) is 70–90% genetically determined, making it largely unresponsive to diet and exercise — but hormonal and inflammatory amplifiers are modifiable.
• An optimal Lp(a) is below 14 mg/dL (30 nmol/L); levels above 50 mg/dL (125 nmol/L) constitute a significant independent cardiovascular risk factor.
• Thyroid dysfunction — including subclinical hypothyroidism — is an underappreciated cause of elevated Lp(a), which is why a full thyroid panel (TSH, free T4, free T3) is clinically relevant when Lp(a) is high.
• Fibrinogen shares an inflammatory pathway with Lp(a): both rise during systemic inflammation, and both independently predict cardiovascular events.
• RNA-targeted therapies like pelacarsen represent the most promising pharmacological future for genetically high Lp(a), while PCSK9 inhibitors and high-dose niacin offer modest reductions today.
• Precision supplementation can address the amplifying factors — thyroid support, omega-3s, and vitamin D status — even when the genetic floor of Lp(a) cannot be lowered through nutrition alone.